Cargando…

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy

Although most differentiated thyroid cancers show excellent prognosis, treating radioiodine refractory differentiated thyroid cancer (RR-DTC) is challenging. Various therapies, including chemotherapy, radiotherapy, and targeted therapy, have been applied for RR-DTC but show limited effectiveness. Re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Chae Moon, Ahn, Byeong-Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649198/ https://www.ncbi.nlm.nih.gov/pubmed/29085335 http://dx.doi.org/10.3389/fendo.2017.00260

Ejemplares similares

Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
por: Aashiq, Mohamed, et al.
Publicado: (2019)

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
por: Jafri, Sabih, et al.
Publicado: (2021)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Do radioiodine-avid lymph nodes from differentiated thyroid cancer on the initial posttherapy scan need repeated (131)I therapy?
por: Jiang, Yongji, et al.
Publicado: (2023)

New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review
por: Wong, Kai-Pun, et al.
Publicado: (2012)

Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers
por: Oh, Ji Min, et al.
Publicado: (2022)

Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer
por: Larson, Steven M., et al.
Publicado: (2017)

Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
por: Liu, Jierui, et al.
Publicado: (2019)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017)

Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer
por: Choi, Yoon Ju, et al.
Publicado: (2021)

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
por: Meng, Chao, et al.
Publicado: (2023)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
por: Sun, Yu-qing, et al.
Publicado: (2022)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2021)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead
por: Satapathy, Swayamjeet, et al.
Publicado: (2022)

Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study
por: Mester, Alexandru, et al.
Publicado: (2020)

Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer
por: Ahn, Byeong-Cheol
Publicado: (2016)

A phase I study of pazopanib in combination with escalating doses of (131)I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine
por: Chow, Laura Q., et al.
Publicado: (2017)

Alterations in Oral Microbiota of Differentiated Thyroid Carcinoma Patients With Xerostomia After Radioiodine Therapy
por: Lin, Baiqiang, et al.
Publicado: (2022)

Nontoxic Goiter (NTG) and Radioiodine: What Do Patients Think About It? Quality of Life in Patients with NTG Before and After 131-I Therapy
por: Kaniuka-Jakubowska, Sonia, et al.
Publicado: (2018)

Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer
por: Gao, Haiyan, et al.
Publicado: (2023)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

SAT520 Efficacy of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers
por: Toro-Tobon, David, et al.
Publicado: (2023)

A semiquantitative study of the optimal whole-body imaging time after (131)I therapy for differentiated thyroid cancer
por: Liu, Shuang, et al.
Publicado: (2022)

The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma
por: van der Boom, Trynke, et al.
Publicado: (2021)

Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma
por: Wang, Congcong, et al.
Publicado: (2021)

Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of (131)I during radioiodine therapy of Graves’ disease
por: Happel, C., et al.
Publicado: (2021)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Ultrasonography Echotexture as a surrogate for Sialadenitis secondary to 131I Radioiodine Therapy for differentiated Thyroid Cancer: a review and metaanalysis
por: Lima, Graziele Aparecida Simões, et al.
Publicado: (2020)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

How to Prepare Endocrinology and Metabolism for Reapplication to MEDLINE
por: Huh, Sun
Publicado: (2017)

Reapplication Requirements for Prescription Assistance Program Mischaracterized
por: Zonca, Kathy
Publicado: (2007)

Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer
por: Yu, Feng, et al.
Publicado: (2021)

Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy
por: Wang, Congcong, et al.
Publicado: (2023)

Radioiodination and Purification of [(131)I]β-CIT and [(131)I]FP-CIT with an Automated Radiosynthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2022)

Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult
por: Zhao, Xianlan, et al.
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Radioiodine-131 Therapy Used for Differentiated Thyroid Cancer Can Impair Titanium Dental Implants: An In Vitro Analysis
por: Piciu, Doina, et al.
Publicado: (2023)

Improving (131)I Radioiodine Therapy By Hybrid Polymer-Grafted Gold Nanoparticles
por: Le Goas, Marine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5t5udhsmhilltirojso67avqpu